Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

Summary

This phase II trial studies how well Linifanib works in treating patients with advanced, refractory colorectal cancer expressing k-Ras mutations. Linifanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2011-06

Primary completion

2012-05

Completion

2013-06

Outcome

Outcome not reported

Stopped: “Interim analysis determined the study did not meet criteria to proceed”

Drugs

Indications